GERON CORP Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
GERON CORP (GERN) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $21.97 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-03-16
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$3.55M, a 116.41% decline year-over-year.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $21.61M, a 224.99% increase year-over-year.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $6.65M.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$3.77M.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $21.97M, a 11.92% decline from fiscal 2021.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $24.95M.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$3.63M, a 218.11% decline from fiscal 2019.
- GERON CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $3.07M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | $21.97M 10-K · filed 2023-03-16 | |||
| 2022-03-31 | -$3.55M 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $24.95M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $19.11M 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $47.36M 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $21.61M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$3.63M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $31.41M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $9.31M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $6.65M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $3.07M 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $10.18M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $7.14M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$3.77M 10-Q · filed 2020-05-28 | |||
| 2018-12-31 | -$5.76M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | -$3.60M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $2.79M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | -$8.42M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $3.52M 10-K · filed 2020-03-12 | |||
| 2017-09-30 | -$2.91M 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | -$6.20M 10-Q · filed 2018-07-31 | |||
| 2017-03-31 | $2.05M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$8.44M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |